U.S. Stock Market Brief: Momentum, Oversold & Breakout Analysis
July 29, 2026LatestU.S. Markets
- 指数分化：道指 +0.93%、标普 +0.13%、纳指 -0.63%
- CXMT 上海上市引爆中国存储竞争恐慌，SNDK -14%
- MU -8.9%、STX -8.5%，SOXX -4.8% 连跌四日
- 康宁指引不及预期跌 12%，拖累光模块全链
- 资金撤 AI 换防守：XLV +2.4%、XLP +2.0%、RSP +1.2%
Today's Watchlist
- 今夜 FOMC：62% 押注维持 3.50%-3.75% 不变
- MSFT / META 今晚财报，AI 资本开支进入交代期
- SNDK $1000 整数关是多空生死线
- REPL 7/30 FDA 专家会，8/2 终裁
- 小米 7/30 晚 7 点澎程技术发布会
Deep Dives (0 names)
No deep-dive names match the current filters
Rapid Scan (2 names)
| Ticker | Close | Change | Score | Direction | One-line take |
|---|---|---|---|---|---|
 REPLUS | $5.35 | -38.01% | 4 | Neutral | Down 38.01% after FDA reviewers deemed the single-arm study 'not interpretable'. RP1 is on its third filing after two complete response letters, with an advisory meeting July 30 and a decision due August 2 — a binary event bet; not participating |
 CAPRUS | $6.57 | -6.08% | 4 | Neutral | Down 6.08% with RSI at an extreme 13.2. Internal disputes over trial data analysis and statistical plans persist ahead of an FDA advisory meeting; event risk in micro-cap biotech is uncontrollable — not participating |